Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Editas (EDIT) delivered earnings and revenue surprises of -311.43% and -75.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates

Intellia Therapeutics

Which of these two small-cap gene-editing stocks is a better investment?

Better Buy:  Editas Medicine vs.  Intellia

bluebird bio

Vertex Pharmaceuticals

A large-cap biotech, a mid-cap biotech, and a small-cap biotech that have one thing in common: great growth prospects.

3  Best Biotech Stocks to Buy for the Next Decade

CRISPR Therapeutics

The technique itself appears to be safe and effective in humans.

First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results

What's expected to be a busy year for CRISPR stocks started off with a thud, not a bang.

Here's Why CRISPR Stocks Fell in January

CAMBRIDGE, Mass. and DALLAS, Jan.  13, 2020  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular immuno-oncology company, announced a strategic research collaboration, license, and option agreement to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture allogeneic engineered natural killer (NK) cells and non-alpha beta T cell medicines for the treatment of cancer.

Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer

CAMBRIDGE, Mass., Jan.  10, 2020  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed Chief Financial Officer, Michelle Robertson. In connection with Ms. Robertson’s appointment, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to Ms. Robertson as inducements material to Ms. Robertson entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4).  The stock option provides for the purchase of up to 120,000 shares of Editas Medicine common stock at a price of $30.65 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Ms. Robertson’s employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Ms. Robertson’s continued service relationship with Editas Medicine through the applicable vesting dates. The restricted stock unit award is for 20,000 shares of Editas Medicine common stock and vests as to 25 percent of the shares on each one-year anniversary of Ms. Robertson’s employment start date until the fourth anniversary of Ms. Robertson’s employment start date, subject to Ms. Robertson’s continued service to Editas Medicine through the applicable vesting dates.

Editas Medicine Reports Inducement Grants to New Chief Financial Officer

Michelle Robertson joins as Chief Financial Officer

Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth

Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.

Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101

Find out which one of these gene-editing stocks makes a better portfolio addition right now.

Better Buy: Crispr Therapeutics vs. Editas

Shares of CRISPR gene-editing companies tumbled Monday after the Chinese scientist who created the world's first genetically edited babies was sentenced to three years behind bars.

Gene-Editing Stocks Dive As Creator Of CRISPR Babies Goes To Prison

Both of these gene-editing stocks are appealing, but which one reigns supreme?

Better Buy: Editas Medicine vs. CRISPR Therapeutics

Does Editas Medicine (EDIT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Editas Medicine (EDIT) Is Up 6.66% in One Week: What You Should Know

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

Why Is Editas (EDIT) Up 28.7% Since Last Earnings Report?

Data support novel approach to develop a best-in-class, durable medicine for people living with hemoglobinopathies Data support novel approach to develop a best-in-class, durable medicine for people living with hemoglobinopathies

Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Celgene

An amended collaboration agreement limited the types of immune cells that will be pursued by the duo, but that could create more value for Editas Medicine in the long run.

Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable

The gene editing pioneer got a boost from a collaborator and a competitor.

Here's Why Editas Medicine Jumped 45.3% in November

Novartis

There’s still a long way to go, but the newcomer is off to a good start.

CRISPR vs. Gene Therapy Round 1: What Investors Need to Know

Sangamo Therapeutics

These gene-editing trailblazers continue advancing exciting new approaches to treating inherited diseases.

Better Buy: Editas Medicine or Sangamo Therapeutics?

A combination of several factors could be behind the biotech's big gain.

Why Editas Medicine Shares Jumped Today

Editas Medicine (EDIT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher

With first patient dosing for EDIT-101 drawing near, Editas is powering forward with other promising medicines and partnerships.

Editas Expands Its Celgene Partnership After Another Strong Quarter

Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q3 2019 Results Earnings Call - Transcript

The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells

Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases

Editas Medicine In The Realm Of Designer Humans

News for Editas Medicine Stock (EDIT)